floxuridine has been researched along with Blood Diseases in 3 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 10.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 9.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 6.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 5.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| " Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index." | 1.27 | Phase II clinical evaluation of doxifluridine. ( Armand, JP; Bastit, P; Cappelaere, P; Fargeot, P; Fumoleau, P; Hurteloup, P; Keiling, R; Kerbrat, P; Metz, R; Schraub, S, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, T | 1 |
| Mishima, H | 1 |
| Ikenaga, M | 1 |
| Murata, K | 1 |
| Ishida, H | 1 |
| Fukunaga, M | 1 |
| Ota, H | 1 |
| Tominaga, S | 1 |
| Ohnishi, T | 1 |
| Amano, M | 1 |
| Ikeda, K | 1 |
| Ikeda, M | 1 |
| Sekimoto, M | 1 |
| Sakamoto, J | 1 |
| Monden, M | 1 |
| Ardalan, B | 1 |
| Kozyreva, O | 1 |
| Tsai, KT | 1 |
| Santos, E | 1 |
| Franceschi, D | 1 |
| Livingstone, A | 1 |
| Lima, M | 1 |
| Hurteloup, P | 1 |
| Armand, JP | 1 |
| Cappelaere, P | 1 |
| Metz, R | 1 |
| Kerbrat, P | 1 |
| Keiling, R | 1 |
| Fumoleau, P | 1 |
| Fargeot, P | 1 |
| Schraub, S | 1 |
| Bastit, P | 1 |
1 review available for floxuridine and Blood Diseases
| Article | Year |
|---|---|
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
2 trials available for floxuridine and Blood Diseases
| Article | Year |
|---|---|
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2007 |
1 other study available for floxuridine and Blood Diseases
| Article | Year |
|---|---|
Phase II clinical evaluation of doxifluridine.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Diseases; Col | 1986 |